Cross‐resistance of imatinib mesylate and 17‐aag in imatinib‐resistant cells that overexpress bcr‐abl [PDF]
Imatinib mesylate (STI571, Gleevec), an inhibitor of the BCRABL tyrosine kinase, is a breakthrough in the treatment of chronic myelogenous leukaemia (CML), as it is capable of producing very high rates of haematological and cytogenetic responses (Druker, 2002).
Julian, Topaly +5 more
openaire +2 more sources
Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib [PDF]
Imatinib mesylate induces complete cytogenetic responses in patients with chronic myeloid leukemia (CML), yet many patients have detectable BCR-ABL transcripts in peripheral blood even after prolonged therapy.
Holyoake, T. +14 more
core +2 more sources
The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines [PDF]
Background Imatinib mesylate, a selective inhibitor of Abl tyrosine kinase, is efficacious in treating chronic myeloid leukaemia (CML) and Ph+ acute lymphoblastic leukaemia (ALL).
Schwarz, Kerstin +18 more
core +2 more sources
Chronic myeloid leukemia patients sensitive and resistant to imatinib treatment show different metabolic responses. [PDF]
The BCR-ABL tyrosine kinase inhibitor imatinib is highly effective for chronic myeloid leukemia (CML). However, some patients gradually develop resistance to imatinib, resulting in therapeutic failure.
Jiye A +15 more
doaj +1 more source
Defining and Managing Imatinib Resistance [PDF]
AbstractWhile imatinib is highly effective therapy, with improving prospects over time for sustained remission and potential to severely limit or eliminate disease progression and transformation, a minority of patients either fail or respond suboptimally to imatinib; as well, disease eradication may not be possible with imatinib.
openaire +2 more sources
Treating Imatinib-Resistant Leukemia: The Next Generation Targeted Therapies
Imatinib (Gleevec/STI-571/CGP57148B, Novartis) is a small-molecule, tyrosine kinase inhibitor developed to target BCR-ABL, c-Kit, and PDGF-R. Through inhibition of these oncogenic kinases, imatinib is effective in the treatment of BCR-ABLpositive ...
Michael R. Burgess, Charles L. Sawyers
doaj +1 more source
PURPOSEIn describing our ten-year experience with treating chronic myeloid leukemia (CML) as part of the Glivec Patient Assistance Program (GIPAP) in rural Rwanda, we evaluate (1) patient characteristics and treatment outcomes, (2) resource-adapted ...
Jennifer Morgan +13 more
doaj +1 more source
Monitoring the development of resistance to the tyrosine kinase inhibitor (TKI) imatinib in chronic myeloid leukemia (CML) patients in the initial chronic phase (CP) is crucial for limiting the progression of unresponsive patients to terminal phase of ...
Rahul Mojidra +6 more
doaj +1 more source
Unravelling the mechanisms of resistance to imatinib mesylate in chronic myeloid leukemia: a proteomic approach [PDF]
Imatinib mesylate is a potent inhibitor of the Bcr-Abl tyrosine kinase, an oncoprotein that plays a key role in the development of chronic myeloid leukemia. Consequently, imatinib is used as front-line therapy for this disease.
Colavita, Irene
core +1 more source
Predictors of Primary Imatinib Resistance in Chronic Myelogenous Leukemia Are Distinct From Those in Secondary Imatinib Resistance [PDF]
Purpose A subset of patients with chronic myelogenous leukemia (CML) do not respond to the tyrosine kinase inhibitor (TKI) imatinib mesylate. Such primary imatinib resistance is distinguished from secondary resistance which reemerges after attainment of cytogenetic remission.
Wenyong W, Zhang +7 more
openaire +2 more sources

